| Cat.No. : |
IL13RA1-051H
Optional Service: Optional requirements on this protein
|
| Product Overview : |
Biotinylated Recombinant Human IL13RA1(Ala27-Thr343) protein, fused to Fc/Avi tag at the C-terminus, was expressed in CHO cells . |
| Description : |
IL13 RA1, also known as IL13R and IL13 RA, is a type I transmembrane protein. Its cDNA encodes a 427 aa precursor protein, with 322 aa extracellular domain, 24 aa transmembrane domain and 60 aa intracellular domain. Within the extracellular domain, human IL13 RA1 shares 75% and 74% homology with mouse and rat IL13 RA1, respectively. IL13 RA1 expresses ubiquitously in all tissues with the highest level in heart, liver, skeletal muscle and ovary (1). As a receptor, IL13 RA1 can function alone or as a heterodimer with IL-4R. Although both IL-4 and IL-13 signal through IL-4R/IL-13 RA1 heterodimer, there are distinct differences. IL-4 binds IL-4R with high affinity then binds IL-13 RA1 with low affinity. In contrast, IL-13 binds IL-13 RA1 with decent affinity, then binds IL-4R with high affinity (2). In addition, the N-terminal Fibronectin type III domain (D1) of IL-13 RA1 is only required for the binding of IL-13 not IL-4 (3,4). After binding to IL-4 or IL-13, the Tyr residues in the cytoplasmic domain of IL-13 RA get phosphorylated and then activate signaling proteins including Jak1, Tyk1, Tyk2, IRS-1, and STAT6 (5, 6). Alternative splicing generates soluble iL-13 RA1 missing the transmembrane domain (7). It not only functions as a decoy receptor for IL-13, but also is able to reduce fasting blood glucose, mediated by IL-4 (8). Higher expression of IL-13 RA1 are found in several cancers, often associated with poor prognosis in patients (9-11). Our Avi-tag Biotinylated human IL-13 RA1 features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity. |
| Source : |
CHO cells |
| Species : |
Human |
| Tag : |
Fc/Avi |
| Predicted N Terminal : |
Ala27 |
| Form : |
Supplied as a 0.2 μm filtered solution in PBS with Trehalose. |
| Bio-activity : |
Measured by its binding ability in a functional ELISA. When Biotinylated Recombinant Human IL13RA1 Fc Chimera Avi-tag is immobilized at 1 µg/mL (100 µL/well), Recombinant Human IL13 binds with an ED50 of 10-80 ng/mL. |
| Molecular Mass : |
93-103 kDa, under reducing conditions |
| Protein length : |
Ala27-Thr343 |
| Endotoxin : |
<0.10 EU per 1 μg of the protein by the LAL method. |
| Purity : |
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining. |
| Applications : |
Bioactivity |
| Storage : |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.6 months from date of receipt, -20 to -70 °C as supplied.1 month, 2 to 8 °C under sterile conditions after opening.3 months, -20 to -70 °C under sterile conditions after opening. |
| SDS-PAGE : |
2 μg/lane Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining.
|
| Binding Activity : |
|
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
